$16.24 Million in Sales Expected for Nurix Therapeutics, Inc. (NASDAQ:NRIX) This Quarter

Analysts expect Nurix Therapeutics, Inc. (NASDAQ:NRIX) to report sales of $16.24 million for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Nurix Therapeutics’ earnings. The lowest sales estimate is $8.80 million and the highest is $35.46 million. Nurix Therapeutics reported sales of $6.69 million during the same quarter last year, which suggests a positive year-over-year growth rate of 142.8%. The business is expected to announce its next earnings results on Tuesday, February 15th.

According to Zacks, analysts expect that Nurix Therapeutics will report full year sales of $38.60 million for the current year, with estimates ranging from $31.20 million to $57.81 million. For the next fiscal year, analysts forecast that the firm will post sales of $55.81 million, with estimates ranging from $35.30 million to $73.14 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Nurix Therapeutics.

Nurix Therapeutics (NASDAQ:NRIX) last announced its earnings results on Thursday, October 14th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.02). Nurix Therapeutics had a negative net margin of 342.27% and a negative return on equity of 29.81%. The business had revenue of $10.25 million for the quarter, compared to the consensus estimate of $8.73 million.

Several brokerages recently commented on NRIX. Robert W. Baird upped their target price on Nurix Therapeutics from $46.00 to $49.00 and gave the company an “outperform” rating in a research report on Thursday, October 28th. SVB Leerink upped their price target on Nurix Therapeutics from $50.00 to $64.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 27th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $53.17.

Shares of Nurix Therapeutics stock traded down $0.74 on Friday, hitting $30.70. 181,635 shares of the company’s stock traded hands, compared to its average volume of 417,716. Nurix Therapeutics has a one year low of $21.53 and a one year high of $52.38. The firm’s fifty day moving average price is $32.66. The company has a market cap of $1.37 billion, a P/E ratio of -12.85 and a beta of 2.25.

In other Nurix Therapeutics news, General Counsel Christine Ring sold 3,200 shares of the firm’s stock in a transaction dated Tuesday, September 7th. The stock was sold at an average price of $35.25, for a total transaction of $112,800.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Gwenn Hansen sold 1,600 shares of the firm’s stock in a transaction dated Tuesday, September 7th. The shares were sold at an average price of $35.00, for a total value of $56,000.00. Following the sale, the insider now owns 15,797 shares in the company, valued at approximately $552,895. The disclosure for this sale can be found here. Over the last three months, insiders have sold 8,000 shares of company stock valued at $269,096. 6.30% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently modified their holdings of the company. Price T Rowe Associates Inc. MD boosted its position in shares of Nurix Therapeutics by 31.0% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 4,051,478 shares of the company’s stock worth $107,486,000 after purchasing an additional 957,773 shares in the last quarter. BlackRock Inc. raised its holdings in Nurix Therapeutics by 19.0% in the 3rd quarter. BlackRock Inc. now owns 2,483,573 shares of the company’s stock worth $74,408,000 after acquiring an additional 396,957 shares during the last quarter. Baker BROS. Advisors LP raised its stake in Nurix Therapeutics by 37.2% during the 1st quarter. Baker BROS. Advisors LP now owns 2,454,082 shares of the company’s stock valued at $76,297,000 after buying an additional 665,161 shares during the last quarter. State Street Corp raised its stake in Nurix Therapeutics by 35.0% during the 2nd quarter. State Street Corp now owns 1,859,468 shares of the company’s stock valued at $49,332,000 after buying an additional 481,606 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in Nurix Therapeutics by 26.1% during the 2nd quarter. Vanguard Group Inc. now owns 1,466,137 shares of the company’s stock valued at $38,896,000 after buying an additional 303,153 shares during the last quarter. 90.57% of the stock is currently owned by hedge funds and other institutional investors.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader with immunomodulatory drug (IMiD) activity for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader without IMiD activity for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

Recommended Story: Environmental, Social, and Governance (ESG) Investing

Get a free copy of the Zacks research report on Nurix Therapeutics (NRIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nurix Therapeutics (NASDAQ:NRIX)

Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.